FDA Inspection 1291782 — Renata Stawerska, MD, PhD
The FDA completed an inspection of Renata Stawerska, MD, PhD on Oct 24, 2025 in Lodz. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Oct 24, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Lodz (Poland)
Additional details
Clinical Investigator (CI)